Xponance, Inc. Nektar Therapeutics Transaction History

Xponance, Inc.

$9.68 Billion
Q2 2024

A detailed history of Xponance, Inc. transactions in Nektar Therapeutics stock. As of the latest transaction made, Xponance, Inc. holds 11,454 shares of NKTR stock, worth $13,401. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,454

Holding current value

$13,401

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.9 - $1.83 $10,308 - $20,960	11,454 New	11,454 $14,000
Q4 2022 Jan 23, 2023	BUY	$2.03 - $4.28 $345 - $727	170 Added 1.67%	10,341 $0
Q3 2022 Oct 24, 2022	BUY	$3.04 - $5.14 $30,919 - $52,278	10,171 New	10,171 $33,000
Q4 2021 Jan 31, 2022	SELL	$10.83 - $18.41 $223,574 - $380,056	-20,644 Closed	0 $0
Q3 2021 Nov 05, 2021	SELL	$13.07 - $18.84 $8,887 - $12,811	-680 Reduced 3.19%	20,644 $371,000
Q2 2021 Aug 12, 2021	BUY	$16.52 - $20.4 $35,038 - $43,268	2,121 Added 11.05%	21,324 $366,000
Q1 2021 May 10, 2021	BUY	$16.56 - $25.46 $6,557 - $10,082	396 Added 2.11%	19,203 $384,000
Q4 2020 Feb 11, 2021	SELL	$15.77 - $19.03 $410 - $494	-26 Reduced 0.14%	18,807 $320,000
Q3 2020 Oct 26, 2020	BUY	$16.59 - $24.79 $45,887 - $68,569	2,766 Added 17.22%	18,833 $312,000
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $270,889 - $376,610	16,067 New	16,067 $372,000

Others Institutions Holding NKTR

# of Institutions

140

Shares Held

135M

Call Options Held

32.8K

Put Options Held

55.5K

Deep Track Capital, LP Greenwich, CT

17.9M
Shares

$20.9 Million
0.73% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$17.7 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13M
Shares

$15.2 Million
0.0% of portfolio
Samlyn Capital, LLC New York, NY

9.46M
Shares

$11.1 Million
0.21% of portfolio
Eventide Asset Management, LLC Boston, MA

7.53M
Shares

$8.81 Million
0.16% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xponance, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Xponance, Inc. with notifications on news.

Account